Academic Publications

Dr. Finn has published under her maiden name, Kelsey M. Stuttgen as well as Kelsey M. Stuttgen Finn.

Finn, K. S., Pacyna, J., Tsou, C. A., Samadder, N. J., & Sharp, R. (2021). Patient-reported anticipated barriers and benefits to sharing cancer genetic risk information with family members. European Journal of Human Genetics, 1-9.

Meagher, K. M., Stuttgen Finn, K., Curtis, S. H., Borucki, J., Beck, A. T., Cheema, A. W., & Sharp, R. R. (2022). Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?. Clinical and translational science, 15(3), 721-731.

Stuttgen, K., Lynch, J., Aufox, S., Bland, S., Chung, W., Halverson, C., Hebbring, S., Hoell, C., Holm, I., Jarvik, G., Kullo, I., Leppig, K., Meyers, M., Prows, C., Milo Rasouly, H., Singh, R., Weisner, G., Williams, J., Wynn, J., Smith, M., Sharp, R. (2021). Returning Negative Results from Large-Scale Genomic Screening: Experiences from the eMERGE III Network.  The American Journal of Medical Genetics Part A, 185(2), pp.508-516.

Stuttgen, K., Pacyna, J., Beck, A., Kullo, I., Sharp, R. (2020). Patient Reactions to Receiving Negative Genomic Screening Results by Mail. Genetics in Medicine. https://doi.org/10.1038/s41436-020-0906-2

Stuttgen, K. M., McCague, A., Bollinger, J. M., Dvoskin, R. L., Shpritz, B., Brandt, J., & Mathews, D. J. (202o). “I wanted more information but I think they were scared I couldn’t handle it:” Whether, When, and How to Communicate Genetic Risk to Minors.” Journal of Genetic Counseling.

Stuttgen, K. M., McCague, A., Bollinger, J. M., Dvoskin, R. L., & Mathews, D. J. (2020). Family Communication Patterns and Challenges of Huntington’s Disease, the Decision to Pursue Presymptomatic Testing, and Test Results. Journal of Huntington’s Disease.

Stuttgen, K. M., Bollinger, J. M., Dvoskin, R. L., MccCague, A., Shpritz, B., Brandt, J., & Mathews, D. J. (2018). Perspectives on Genetic Testing and Return of Results from the First Cohort of Presymptomatically Tested Individuals At Risk of Huntington Disease. Journal of Genetic Counseling. doi:10.1007/s10897-018-0274-0

 McCague, A., Stuttgen., K. M., Bollinger, J. M., Dvoskin, R. L., Shpritz, B., Brandt, J., & Mathews, D. J. (2020). “I feel like we've sort of been ignored for a long time”: A qualitative assessment of challenges faced by cystic fibrosis and Duchenne muscular dystrophy carriers.” Under Review.

Stuttgen, K. M., Dvoskin, R. L., Bollinger, J. M., McCague, A., Shpritz, B., Brandt, J., & Mathews, D. J. (2018). Risk Perception Before and After Presymtomatic Genetic Testing for Huntington’s Disease: Not Always What One Might Expect. Molecular Genetics & Genomics in Medicine.

Stuttgen, K., Croessmann, S., Fetting, J., Stearns, V., Nunes, R., Connolly, R. M., & Park, B. H. (2019). Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. JAMA Oncology.

Stuttgen, K., Pacyna, J., Kullo, I., & Sharp, R. (2020). Neutral, Negative, or Negligible? Changes in Patient Perceptions of Disease Risk Following Receipt of a Negative Genomic Screening Result. Journal of Personalized Medicine, 10(2), 24.

Lynch JA, Sharp RR, Aufox SA, Bland ST, Blout C, Bowen DJ, Buchanan AH, Halverson C, Harr M, Hebbring SJ, Henrikson N, Hoell C, Holm IA, Jarvik G, Kullo IJ, Kochan DC, Larson EB, Lazzeri A, Leppig KA, Madden J, Marasa M, Myers MF, Peterson J, Prows CA, Kulchak Rahm A, Ralston J, Milo Rasouly H, Scrol A, Smith ME, Sturm A, Stuttgen K, Wiesner G, Williams MS, Wynn J, Williams JL. (2020). Understanding the Return of Genomic Sequencing Results Process: Content Review of Participant Summary Letters in the eMERGE Research Network. Journal of Personalized Medicine, 10(2):38.

Stuttgen, K. M. (2018). Genetic Testing, Interpretation, and Communication: Exploration Across Disciplines. PhD diss., Johns Hopkins University..

McCague, A., Stuttgen., K. M., Bollinger, J. M., Dvoskin, R. L., Shpritz, B., Brandt, J., & Mathews, D. J. (2019). The impact of disease-modifying therapies on reproductive decision-making in cystic fibrosis and Duchenne muscular dystrophy carriers. Under Review.